Somatostatin receptor agonist formulations

US11672843B2 · kind B2 · utility

Assignee

• CAMURUS AB · SE

Inventors

• Catalin Nistor · Lund, SE
• Markus Johnsson · Lund, SE
• Fredrik Tiberg · Lund, SE

Key dates

• Filing date: May 24, 2013
• Grant date: Jun 13, 2023
• Expiry date: May 24, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/183
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.